Childhood-onset anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) necrotizing myopathy needs to be distinguished from muscular dystrophy

A case study

Yuka Hama, Madoka Mori-Yoshimura, Hirofumi Komaki, Shigeaki Suzuki, Hitoshi Kohsaka, Ichizo Nishino, Yuji Takahashi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A 24-year-old woman visited our hospital with a complaint of walking disability. She had no family history of consanguineous marriage, and her developmental history was unremarkable, with good physical performance just before the onset. At the age of 13, she developed difficulty in walking and visited a pediatrician. Her serum CK level was 10,000 IU/l and she was diagnosed with muscular dystrophy by muscle biopsy. At the age of 16, she became wheelchair dependent and was admitted to our hospital. Physical examination revealed diffuse muscle atrophy and proximal weakness, with no calf hypertrophy or selectivity of muscle involvement. Needle EMG and MR images indicated inflammatory myopathy. Muscle biopsy revealed necrotic and regenerating fibers and lymphocyte infiltration. She was re-diagnosed with inflammatory myopathy and recovered walking capacity after immunotherapy. Subsequently, she was tested positive for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies. To distinguish treatable inflammatory myopathy from muscular dystrophy, a comprehensive assessment of patient history, family history, selectivity of muscle involvement, findings suggestive of inflammation in EMG and CT/MR imaging, and muscle pathology is necessary.

Original languageEnglish
Pages (from-to)567-572
Number of pages6
JournalClinical Neurology
Volume57
Issue number10
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Muscular Dystrophies
Muscular Diseases
Oxidoreductases
Myositis
Muscles
Walking
Mobility Limitation
Biopsy
Wheelchairs
Muscular Atrophy
Marriage
Immunotherapy
Hypertrophy
Physical Examination
Needles
3-hydroxy-3-methylglutaryl-coenzyme A
Lymphocytes
Pathology
Inflammation
Antibodies

Keywords

  • Anti-HMGCR antibodies
  • Childhood
  • Immune mediated necrotizing myopathy
  • Muscular dystrophy
  • Statin

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Childhood-onset anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) necrotizing myopathy needs to be distinguished from muscular dystrophy : A case study. / Hama, Yuka; Mori-Yoshimura, Madoka; Komaki, Hirofumi; Suzuki, Shigeaki; Kohsaka, Hitoshi; Nishino, Ichizo; Takahashi, Yuji.

In: Clinical Neurology, Vol. 57, No. 10, 01.01.2017, p. 567-572.

Research output: Contribution to journalArticle

Hama, Yuka ; Mori-Yoshimura, Madoka ; Komaki, Hirofumi ; Suzuki, Shigeaki ; Kohsaka, Hitoshi ; Nishino, Ichizo ; Takahashi, Yuji. / Childhood-onset anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) necrotizing myopathy needs to be distinguished from muscular dystrophy : A case study. In: Clinical Neurology. 2017 ; Vol. 57, No. 10. pp. 567-572.
@article{b66ee5369d394e93bac92f163d132063,
title = "Childhood-onset anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) necrotizing myopathy needs to be distinguished from muscular dystrophy: A case study",
abstract = "A 24-year-old woman visited our hospital with a complaint of walking disability. She had no family history of consanguineous marriage, and her developmental history was unremarkable, with good physical performance just before the onset. At the age of 13, she developed difficulty in walking and visited a pediatrician. Her serum CK level was 10,000 IU/l and she was diagnosed with muscular dystrophy by muscle biopsy. At the age of 16, she became wheelchair dependent and was admitted to our hospital. Physical examination revealed diffuse muscle atrophy and proximal weakness, with no calf hypertrophy or selectivity of muscle involvement. Needle EMG and MR images indicated inflammatory myopathy. Muscle biopsy revealed necrotic and regenerating fibers and lymphocyte infiltration. She was re-diagnosed with inflammatory myopathy and recovered walking capacity after immunotherapy. Subsequently, she was tested positive for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies. To distinguish treatable inflammatory myopathy from muscular dystrophy, a comprehensive assessment of patient history, family history, selectivity of muscle involvement, findings suggestive of inflammation in EMG and CT/MR imaging, and muscle pathology is necessary.",
keywords = "Anti-HMGCR antibodies, Childhood, Immune mediated necrotizing myopathy, Muscular dystrophy, Statin",
author = "Yuka Hama and Madoka Mori-Yoshimura and Hirofumi Komaki and Shigeaki Suzuki and Hitoshi Kohsaka and Ichizo Nishino and Yuji Takahashi",
year = "2017",
month = "1",
day = "1",
doi = "10.5692/clinicalneurol.cn-001040",
language = "English",
volume = "57",
pages = "567--572",
journal = "Clinical Neurology",
issn = "0009-918X",
publisher = "Societas Neurologica Japonica",
number = "10",

}

TY - JOUR

T1 - Childhood-onset anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (anti-HMGCR) necrotizing myopathy needs to be distinguished from muscular dystrophy

T2 - A case study

AU - Hama, Yuka

AU - Mori-Yoshimura, Madoka

AU - Komaki, Hirofumi

AU - Suzuki, Shigeaki

AU - Kohsaka, Hitoshi

AU - Nishino, Ichizo

AU - Takahashi, Yuji

PY - 2017/1/1

Y1 - 2017/1/1

N2 - A 24-year-old woman visited our hospital with a complaint of walking disability. She had no family history of consanguineous marriage, and her developmental history was unremarkable, with good physical performance just before the onset. At the age of 13, she developed difficulty in walking and visited a pediatrician. Her serum CK level was 10,000 IU/l and she was diagnosed with muscular dystrophy by muscle biopsy. At the age of 16, she became wheelchair dependent and was admitted to our hospital. Physical examination revealed diffuse muscle atrophy and proximal weakness, with no calf hypertrophy or selectivity of muscle involvement. Needle EMG and MR images indicated inflammatory myopathy. Muscle biopsy revealed necrotic and regenerating fibers and lymphocyte infiltration. She was re-diagnosed with inflammatory myopathy and recovered walking capacity after immunotherapy. Subsequently, she was tested positive for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies. To distinguish treatable inflammatory myopathy from muscular dystrophy, a comprehensive assessment of patient history, family history, selectivity of muscle involvement, findings suggestive of inflammation in EMG and CT/MR imaging, and muscle pathology is necessary.

AB - A 24-year-old woman visited our hospital with a complaint of walking disability. She had no family history of consanguineous marriage, and her developmental history was unremarkable, with good physical performance just before the onset. At the age of 13, she developed difficulty in walking and visited a pediatrician. Her serum CK level was 10,000 IU/l and she was diagnosed with muscular dystrophy by muscle biopsy. At the age of 16, she became wheelchair dependent and was admitted to our hospital. Physical examination revealed diffuse muscle atrophy and proximal weakness, with no calf hypertrophy or selectivity of muscle involvement. Needle EMG and MR images indicated inflammatory myopathy. Muscle biopsy revealed necrotic and regenerating fibers and lymphocyte infiltration. She was re-diagnosed with inflammatory myopathy and recovered walking capacity after immunotherapy. Subsequently, she was tested positive for anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) antibodies. To distinguish treatable inflammatory myopathy from muscular dystrophy, a comprehensive assessment of patient history, family history, selectivity of muscle involvement, findings suggestive of inflammation in EMG and CT/MR imaging, and muscle pathology is necessary.

KW - Anti-HMGCR antibodies

KW - Childhood

KW - Immune mediated necrotizing myopathy

KW - Muscular dystrophy

KW - Statin

UR - http://www.scopus.com/inward/record.url?scp=85036614771&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85036614771&partnerID=8YFLogxK

U2 - 10.5692/clinicalneurol.cn-001040

DO - 10.5692/clinicalneurol.cn-001040

M3 - Article

VL - 57

SP - 567

EP - 572

JO - Clinical Neurology

JF - Clinical Neurology

SN - 0009-918X

IS - 10

ER -